Pomalidomide plus low-dose dexamethasone in patients with relapsed/refractory multiple myeloma and moderate renal impairment: a pooled analysis of three clinical trials

Leukemia and Lymphoma

Volumn 57, Issue 12, 2016, Pages 2833-2838

  Siegel, David S ^a   Weisel, Katja C ^b   Dimopoulos, Meletios A ^c   Baz, Rachid ^d   Richardson, Paul ^e   Delforge, Michel ^f   Song, Kevin W ^g   San Miguel, Jesus F ^h   Moreau, Philippe ⁱ   Goldschmidt, Hartmut ^j   Cavo, Michele ^k   Jagannath, Sundar ^l   Yu, Xin ^m   Hong, Kevin ^m   Sternas, Lars ^m   Zaki, Mohamed ^m   Palumbo, Antonio ⁿ  

^a HACKENSACK UNIVERSITY MEDICAL CENTER   (United States)

^b UNIVERSITY HOSPITAL TÜBINGEN   (Germany)

^c UNIVERSITY OF ATHENS   (Greece)

^d H LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE   (United States)

^e DANA FARBER CANCER INSTITUTE   (United States)

^f UNIVERSITY HOSPITALS LEUVEN   (Belgium)

^g VANCOUVER GENERAL HOSPITAL   (Canada)

^h UNIVERSITY CLINIC OF NAVARRA   (Spain)

ⁱ HÔTEL DIEU   (France)

^j UNIVERSITY OF HEIDELBERG   (Germany)

^k UNIVERSITY OF BOLOGNA   (Italy)

^l MOUNT SINAI HOSPITAL   (United States)

^m CELGENE CORPORATION   (United States)

ⁿ UNIVERSITY OF TURIN   (Italy)

more..

Author keywords

IMiD; pomalidomide; relapsed refractory multiple myeloma; renal impairment

Indexed keywords

CREATININE; DEXAMETHASONE; POMALIDOMIDE; ANTINEOPLASTIC AGENT; THALIDOMIDE;

ADULT; AGED; ANEMIA; ARTICLE; CANCER CHEMOTHERAPY; CANCER PATIENT; CANCER RECURRENCE; CANCER SURVIVAL; CLINICAL EFFECTIVENESS; CLINICAL TRIAL (TOPIC); CREATININE CLEARANCE; DEEP VEIN THROMBOSIS; DRUG DOSE REDUCTION; DRUG WITHDRAWAL; FEBRILE NEUTROPENIA; HUMAN; INFECTION; LOW DRUG DOSE; LUNG EMBOLISM; MAJOR CLINICAL STUDY; MODERATE RENAL IMPAIRMENT; MULTIPLE MYELOMA; NEUTROPENIA; OVERALL SURVIVAL; PATIENT SAFETY; PERIPHERAL NEUROPATHY; PNEUMONIA; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; THROMBOCYTOPENIA; TREATMENT DURATION; TREATMENT RESPONSE; ANALOGS AND DERIVATIVES; CANCER STAGING; COMPLICATION; DRUG RESISTANCE; FEMALE; KIDNEY FAILURE; MALE; MIDDLE AGED; PATHOLOGY; PATHOPHYSIOLOGY; RECURRENT DISEASE; RETREATMENT; TREATMENT OUTCOME; VERY ELDERLY;

ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; DEXAMETHASONE; DRUG RESISTANCE, NEOPLASM; FEMALE; HUMANS; MALE; MIDDLE AGED; MULTIPLE MYELOMA; NEOPLASM STAGING; RECURRENCE; RENAL INSUFFICIENCY; RETREATMENT; THALIDOMIDE; TREATMENT OUTCOME;

EID: 84976262187     PISSN: 10428194     EISSN: 10292403     Source Type: Journal    
DOI: 10.1080/10428194.2016.1177181     Document Type: Article

References (33)

1. S.M.Korbet, M.M.Schwartz Multiple myeloma. J Am Soc Nephrol. 2006;17:2533–2545.
2. E.Kastritis, A.Anagnostopoulos, M.Roussou,. Reversibility of renal failure in newly diagnosed multiple myeloma patients treated with high dose dexamethasone-containing regimens and the impact of novel agents. Haematologica. 2007;92:546–549.
3. M.A.Dimopoulos, S.Delimpasi, E.Katodritou,. Significant improvement in the survival of patients with multiple myeloma presenting with severe renal impairment after the introduction of novel agents. Ann Oncol. 2014;25:195–200.
4. R.A.Kyle, M.A.Gertz, T.E.Witzig,. Review of 1027 patients with newly diagnosed multiple myeloma. Mayo Clin Proc. 2003;78:21–33.
5. M.A.Dimopoulos, E.Terpos, A.Chanan-Khan,. Renal impairment in patients with multiple myeloma:a consensus statement on behalf of the International Myeloma Working Group. J Clin Oncol. 2010;28:4976–4984.
6. A.A.Chanan-Khan, J.F.San Miguel, S.Jagannath,. Novel therapeutic agents for the management of patients with multiple myeloma and renal impairment. Clin Cancer Res. 2012;18:2145–2163.
7. H.Goldschmidt, H.Lannert, J.Bommer,. Multiple myeloma and renal failure. Nephrol Dial Transplant. 2000;15:301–304.
8. L.M.Knudsen, M.Hjorth, E.Hippe Renal failure in multiple myeloma:reversibility and impact on the prognosis. Nordic Myeloma Study Group. Eur J Haematol. 2000;65:175–181.
9. M.A.Dimopoulos, M.Rossou, M.Gkotzmanidou,. The role of novel agents on the reversibility of renal impairment in newly diagnosed symptomatic patients with multiple myeloma. Leukemia. 2013;27:423–429.
10. K.Uttervall, A.D.Duru, J.Lund,. The use of novel drugs can effectively improve response, delay relapse and enhance overall survival in multiple myeloma patients with renal impairment. PLoS One. 2014;9:e101819.
11. M.Attal, J.L.Harousseau, S.Leyvraz,. Maintenance therapy with thalidomide improves survival in patients with multiple myeloma. Blood. 2006;108:3289–3294.
12. S.K.Kumar, S.V.Rajkumar, A.Dispenzieri,. Improved survival in multiple myeloma and the impact of novel therapies. Blood. 2008;111:2516–2520.
13. W.I.Gonsalves, N.Leung, S.V.Rajkumar,. Improvement in renal function and its impact on survival in patients with newly diagnosed multiple myeloma. Blood Cancer J. 2015;5:e296.
14. H.Quach, D.Ritchie, A.K.Stewart,. Mechanism of action of immunomodulatory drugs (IMiDs) in multiple myeloma. Leukemia. 2010;24:22–32.
15. M.A.Dimopoulos, A.Palumbo, P.Corradini,. The STRATUS (MM-010) trial:a single-arm, phase 3B study evaluating safety and efficacy of pomalidomide + low-dose dexamethasone in patients with refractory or relapsed and refractory multiple myeloma. Haematologica. 2015;100:(Supplement). Abstract 273.
16. P.G.Richardson, D.S.Siegel, R.Vij,. Pomalidomide alone or in combination with low-dose dexamethasone in relapsed and refractory multiple myeloma:a randomized phase 2 study. Blood. 2014;123:1826–1832.
17. J.San Miguel, K.Weisel, P.Moreau,. Pomalidomide plus low-dose dexamethasone versus high-dose dexamethasone alone for patients with relapsed and refractory multiple myeloma (MM-003):a randomised, open-label, phase 3 trial. Lancet Oncol. 2013;14:1055–1066.
18. Pomalyst (pomalidomide) [package insert]. Summit, NJ:Celgene Corporation; 2015.
19. Imnovid (pomalidomide) [summary of product characteristics]. Uxbridge, UK:Celgene Europe; 2015.
20. R.Botev, J.P.Mallie, J.F.Wetzels,. The clinician and estimation of glomerular filtration rate by creatinine-based formulas:current limitations and quo vadis. Clin J Am Soc Nephrol. 2011;6:937–950.
21. National Kidney Foundation. K/DOQI clinical practice guidelines for chronic kidney disease:evaluation, classification, and stratification. Am J Kidney Dis. 2002;39:S1–S266.
22. N.Chen, H.Lau, L.Kong,. Pharmacokinetics of lenalidomide in subjects with various degrees of renal impairment and in subjects on hemodialysis. J Clin Pharmacol. 2007;47:1466–1475.
23. M.A.Dimopoulos, D.Christoulas, M.Roussou,. Lenalidomide and dexamethasone for the treatment of refractory/relapsed multiple myeloma:dosing of lenalidomide according to renal function and effect on renal impairment. Eur J Haematol. 2010;85:1–5.
24. M.Hoffmann, C.Kasserra, J.Reyes,. Absorption, metabolism and excretion of [14C]pomalidomide in humans following oral administration. Cancer Chemother Pharmacol. 2013;71:489–501.
25. D.W.Cockcroft, M.H.Gault Prediction of creatinine clearance from serum creatinine. Nephron. 1976;16:31–41.
26. K.C.Weisel, M.A.Dimopoulos, P.Moreau,. Analysis of MM-003 patients with moderate renal impairment using pomalidomide + low-dose dexamethasone (POM + LoDEX) vs. high-dose dexamethasone (HiDEX) in relapsed/refractory multiple myeloma (RRMM). Haematologica. 2013;98:(Supplement). Abstract 244.
27. X.Leleu, M.Attal, B.Arnulf,. Pomalidomide plus low dose dexamethasone is active and well tolerated in bortezomib and lenalidomide-refractory multiple myeloma:Intergroupe Francophone du Myélome 2009-02. Blood. 2013;121:1968–1975.
28. P.G.Richardson, D.Siegel, R.Baz,. Phase 1 study of pomalidomide MTD, safety, and efficacy in patients with refractory multiple myeloma who have received lenalidomide and bortezomib. Blood. 2013;121:1961–1967.
29. K.Weisel, M.Dimopoulos, P.Moreau,. Pomalidomide plus low-dose dexamethasone (POM + LoDEX) versus high-dose dexamethasone (HiDEX) in relapsed/refractory multiple myeloma (RRMM):MM-003 analysis of patients (pts) with moderate renal impairment (RI). J Clin Oncol. 2013;31:(Supplement). Abstract 8527.
30. D.S.Siegel, P.G.Richardson, R.Baz,. Pomalidomide (POM) with low-dose dexamethasone (LoDEX) in patients with relapsed and refractory multiple myeloma (RRMM):impact of renal function on patient outcomes. Blood. 2012;120:(Supplement). Abstract 4072.
31. M.A.Dimopoulos, X.Leleu, A.Palumbo,. Expert panel consensus statement on the optimal use of pomalidomide in relapsed and refractory multiple myeloma. Leukemia. 2014;28:1573–1585.
32. J.Matous, D.Siegel, S.Lonial,. MM-008:a phase 1 trial evaluating pharmacokinetics and tolerability of pomalidomide + low-dose dexamethasone in patients with relapsed or refractory and refractory multiple myeloma and renal impairment. Blood. 2014;124:(Supplement). Abstract 4730.
33. P.Sonneveld, N.Heyne, E.Kueenburg,. MM-013:an ongoing phase 2 trial of pomalidomide and low-dose dexamethasone (POM + LoDEX) in relapsed/refractory multiple myeloma (RRMM) with moderate or severe renal impairment (RI), including patients (pts) undergoing hemodialysis. J Clin Oncol. 2014;32:TPS8626.